Amgen Wins Ban On Teva's Generic Version Of Sensipar
A federal judge on Friday barred Teva Pharmaceutical Industries Ltd. and its subsidiary Barr Laboratories Inc. from selling a generic version of Amgen Inc.'s kidney drug Sensipar until the patents covering...To view the full article, register now.
Already a subscriber? Click here to view full article